Description
Lercanidipine is a dihydropyridine calcium channel blocker. It significantly countered wall thickening and luminal narrowing on small sized arteries. This compound and other similar dihydropyridine-type Ca2+ antagonists exert protective effect on retinal that include reduced thickness of retina and of inner plexiform, outer nuclear and layer of inner and outer segments plus outer limiting layer, and loss of ganglionic neurons. Lercanidipine consistently decreased MMP-9 activity and reduced oxidative stress in hypertensive patients. Lercanidipine treatment of spontaneously hypertensive rats (SHR) during 6 weeks was able to revert the deleterious effects of hypertension on cortical bone density and on the number of TRAP+ cells in the tibia of SHR.
References
Sabbatini M1, Leonardi A, Testa R, et al. Effects of dihydropyridine-type Ca2+ antagonists on the renal arterial tree in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 2002 Jan;39(1):39-48. PMID: 11743226.
Sabbatini M1, Tomassoni D, Di Tullio MA, Amenta F. Neuroprotective effect of treatment with calcium antagonists on hypertensive retina. Clin Exp Hypertens. 2002 Oct-Nov;24(7-8):727-40. PMID: 12450247.
Martinez ML1, Lopes LF, Coelho EB, et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol. 2006 Jan;47(1):117-22. PMID: 16424795.
Bastos MF1, Vasconcelos de Araújo I, et al. Effects of lercanidipine on bone density and bone repair in spontaneously hypertensive rats. Implant Dent. 2013 Feb;22(1):49-54. doi: 10.1097/ID.0b013e3182777650. PMID: 23287976.
